Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

J Res Educ Indian Med . 1982; 1(1): 51-59


PRIMARY AND SECONDARY PREVENTION OF ISCHAEMIC HEART DISEASE BY GUGGULU (C. Mukal )

B. N. UPADHYAYl, Y. B. TRIPATHI, S. N. TRIPATHI.




Abstract

The role of C. mukul (Guggulu) in the prevention and treatment of Ischemic Heart Disease has been assessed in 135 patients. Among them 25 patients belong to the control group and 110 patients in the treated group. In order to establish the effect of guggulu on I. H. D. patients, clinical improvement, changes in serum lipids and changes in E. C. G. before and after the treatment have been observed. A fall of 27% in serum cholesterol, 36% in serum triglyceride, 20% in phospholipids and 37% in free fatty acid has been recorded at the end or three months' treatment. As regards the improvement in pericardial pain and dyspnoea on effort, the patients having grade 11 and I were completely relieved. Reduction in weight by 1 kg. per month on an average has been recorded. Regarding E. C. G. at the end of three months, out of 50 E. C. G. proved cases, 14% cases showed the improvement in S-T segment depression and in the inversion of T-wave. Thus in short-term trial, the hypocholesterolemic and hypolipidemic effect of C. mukul is established.

Key words: Prevention of IHD, Ischemic Heart Disease, hypo-cholesterolemic, hypolipidemic, C. mukul, Guggulu






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.